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Abstract 
Complex formation processes of the (O,N) donor ligands 6-methylpicolinic acid (6-Mepic), 
quinoline-2-carboxylic acid (2-QA) and 3-isoquinolinecarboxylic acid (3-iQA) with the 
organometallic moiety (η5-pentamethylcyclopentadienyl)rhodium(III) (RhCp*) were studied in 
aqueous solution by the combined use of pH-potentiometry, 1H NMR spectroscopy and UV-
Vis spectrophotometry. The solid phase structures of the [RhCp*(L)Cl] complexes bearing 6-
Mepic and 2-QA were characterized by single-crystal X-ray diffraction analysis. Studies 
revealed the exclusive formation of mono complexes of the form [RhCp*(L)(H2O)]+ 
(L = deprotonated form of the ligands) and [RhCp*(L)(OH)]. The positively charged aqua 
species predominate at physiological pH even in the micromolar concentration range. The 
H2O/Cl− co-ligand exchange constants showed that all complexes preferably retain the 
chlorido ligand at the third coordination site at chloride ion concentrations present in the 
serum. In addition in vitro cytotoxicity of these [RhCp*(L)Cl] complexes was evaluated in 
three human cancer cell lines (A549, SW480 and CH1/PA-1) where they showed minor 
cytotoxic potency. 
Introduction 
The field of modern metal-based anticancer drug research was initiated in the late 1960s by 
the discovery of cisplatin, which is still one of the leading agents in clinical use to treat 
cancer. The application of cisplatin is often limited by the appearance of side-effects and 
intrinsic or acquired resistance phenomena [1-3]. In this context, other metals of the platinum 
group were chosen as a core for similar complexes, intended to convey desirable 
pharmacological properties. In the early stages, research concentrated on Ru(III) complexes, 
but later a wider range of metals attracted notice in the development of new anticancer 
compounds. Prominent representatives of this compound class are KP1019 (indazolium 
trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) [4] as well as its sodium salt IT-139 (NKP-
1339) [5] and NAMI-A (imidazolium trans-[tetrachlorido(1H-
imidazole)(dimethylsulfoxide)ruthenate(III)]) [6], all of which have been characterized in a 
variety of studies especially with regard to their growth inhibitory effects on cancer cells. IT-
139 was selected as lead candidate for further clinical development due to its remarkable in 
vivo activity accompanied by low general toxicity as demonstrated in a phase I/IIa clinical 
study [5]. Investigations were undertaken to elucidate the mechanism of action of this Ru(III) 
complex, resulting in the so-called “activation by reduction” hypothesis which indicates that 
the complex with its metal center in the reduced form accounts for the activity of the 
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compound. Therefore, half-sandwich Ru(II)- as well as Os(II)-arene complexes are 
extensively being investigated, and some of them are able to circumvent resistances of 
cancer cells due to novel mechanisms of action by addressing different targets within the cell 
[7,8].  
To extend the scope of possible organometallic compounds with anticancer properties, 
Rh(III)-based complexes have been developed. Rh(III)-cyclopentadienyl complexes are 
isoelectric with Ru(II)-arene complexes and have some chemically attractive properties such 
as increased aqueous solubility and faster ligand exchange kinetics [9,10]. Recently more 
and more studies have focused on their antitumor activity [9,11-15]. Among the first reports 
dealing with the anticancer properties of Rh(III) compounds were those investigating the salt 
RhCl3 and its simple complexes, such as mer-[RhCl3(NH3)3] [16,17]. Promising 
antiproliferative activities of organometallic Rh(III) complexes based on (N,N) donating 
polypyridyl ligands, with IC50 values in the low micromolar concentration range, have been 
reported by Sheldrick and co-workers [18-21]. Another very interesting concept involving 
dirhodium(II,II) complexes that preferentially bind to the nucleobases of RNA and DNA, 
thereby disrupting protein synthesis and cell proliferation, has been developed by Dunbar 
and co-workers [22-24]. Their research showed that the exchange of photo-labile acetonitrile 
ligands coordinated to the oxypyridine-bridged dirhodium core by aqua ligands could be 
significantly accelerated upon light irradiation and was also accompanied by a 16-fold 
increase in cytotoxicity. The oxygen-independent activation of those complexes is a clear 
advantage over established sensitizers commonly used in photodynamic therapy [24]. 
Soldevila-Barreda et al. developed a compound class based on organorhodium Rh(η5-
pentamethylcyclopentadienyl) (RhCp*) complexes and their Ru(η6-p-cymene) analogues 
equipped with redox active sulfonamido ethylenediamine ligands. Those complexes showed 
significant catalytic activity in the conversion of NAD+ to NADH in cancer cells [25,26], 
indicating that the redox modulation of living cells could be an innovative concept among the 
new cancer treatment strategies. 
Numerous studies on organometallic half-sandwich complexes have demonstrated that the 
type of the mono- or bidentate co-ligand(s) has a pronounced effect on physico-chemical 
and biological properties, such as their stability in aqueous solution and lipophilicity, which 
can influence cellular uptake, pharmacokinetics, and ultimately the biological activity. 
Therefore our research has focused on detailed analyses to illuminate correlations between 
complex architectures and their most important characteristics. Recently, we have reported 
on our investigations with RhCp* complexes of interesting (O–,O) donating 3-hydroxy-4-
pyrones (maltol, allomaltol) [27] and 1,2-dimethyl-3-hydroxy-pyridin-4(1H)-one (deferiprone, 
dhp) [28]. These metal complexes have shown moderate cytotoxicity with IC50 values in the 
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range of 50–165 µM in human cancer cell lines (CH1/PA-1, SW480 and A549). A different 
test series wherein RhCp* complexes formed with 2-picolinic acid (pic) [28] and the simple 
bidentate alkylamino and aromatic N-donor ligands, namely ethylenediamine and 2,2ʹ-
bipyridine (bpy), were examined and revealed negligible cytotoxicity [21].  
Detailed solution equilibrium studies of RhCp* complex formation with various ligands are 
fairly rare in the literature [29-31], especially such that provide stability constants. Our 
previous studies indicated that mono complexes formed with maltol and allomaltol 
predominate at physiological pH and decompose partially at micromolar concentrations [27]. 
While complexes of deferiprone, picolinic acid, ethylenediamine, bpy and 8-hydroxyquinoline 
are sufficiently to outstandingly stable, no direct relationship can be established between 
their activity and their stability in aqueous solution [28,32,33]. It is a reasonable hypothesis 
that the increased chloride ion affinity of RhCp* complexes, just like in case of analogous 
Ir(III)-Cp* and some Ru(II)-arene compounds [34-36], may correlate with the poor in vitro 
anticancer activity. On the other hand several other physicochemical factors such as 
lipophilicity, redox and kinetic properties etc. may influence the pharmacokinetic and 
pharmacodynamic behavior of a metallodrug.  
Herein we investigate the effect of 6-methylation or benzene conjugation of the (O–,N) donor 
picolinic acid on the stability, lipophilicity and the biological activity of the respective RhCp* 
complexes. For these studies 6-methylpicolinic acid (6-Mepic), quinoline-2-carboxylic acid 
(quinaldic acid, 2-QA) and 3-isoquinolinecarboxylic acid (3-iQA) (see Chart 1) were chosen 
as bidentate ligands. According to a recent study, 2-QA itself possesses antiproliferative 
activity [37]. The Ru(II)(η6-p-cymene) complex of 3-iQA has also been reported to show 
considerable antiproliferative potential, whereas the complex formed with 
6-methylpicolinic acid (6-Mepic) exerted only low efficacy [38]. Herein, we report data on 
solution equilibria including complexation and chlorido/aqua co-ligand exchange processes 
of RhCp* complexes of 6-Mepic (1), 2-QA (2) and 3-iQA (3) acquired by the combined use of 
pH-potentiometry, 1H NMR spectroscopy, and UV–visible (UV-Vis) spectrophotometry. The 
n-octanol/water distribution coefficients at physiological pH (D7.4) were determined for the 
complexes at various chloride ion concentrations. Complexes 1–3 were characterized by 
standard analytical methods, their biological activity was evaluated in three different human 
cancer cell lines and two of the complexes (1·CH2Cl2 and 2) were suitable for X-ray 
diffraction analysis. 
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Chart 1. General chemical structures of the [RhCp*(L)Cl] complexes formed with 6-Mepic (1), 2-QA 
(2) and 3-iQA (3) and the chemical formulae of ligands in their neutral forms. 
Results and Discussion 
Synthesis and characterization of organometallic Rh(III) complexes  
The Rh(III) precursor [RhCp*(µ-Cl)Cl]2 was synthesized according to literature [39]. The 
RhCp* complexes of 6-Mepic, 2-QA, and 3-iQA (Chart 1) were obtained following the 
established procedure described by Abbott et al. [40] using sodium methoxide for the 
deprotonation of the ligands followed by reaction with the dimeric Rh(III) precursor at room 
temperature. Pure compounds were isolated after extraction with CH2Cl2, yielding 64% (1), 
61% (2) and 53% (3), respectively.  
The organometallic Rh(III) complexes were characterized by means of standard analytical 
methods and their purity was verified by elemental analysis. The 1H NMR spectra of 1–3 
confirm the coordination of the anionic ligand scaffolds to the organorhodium fragment, 
manifesting itself in a slight downfield shift of the Cp* methyl groups and H5 of 6-Mepic. 
Similar observations were made for the analogous Ru(II)(η6-p-cymene) complex of 6-Mepic 
[38]. In the case of the 3-iQA-based complex 3, all ligand protons showed a more or less 
pronounced upfield shift upon coordination to the metal center compared to the free ligand. 
In general, signals representing protons next to the carboxylic group were shifted distinctly 
upon coordination (Figures S1-S3).  
Single crystals of complexes 1·CH2Cl2 and 2 were obtained by the slow diffusion method 
from CH2Cl2/n-hexane and the results of the X-ray diffraction studies are shown in Figures 1 
and 2, respectively. Crystallographic data are presented in Table S1, and selected bond 
lengths and angles are listed in the legends of Figures 1 and 2 and in Table S2. In these 
complexes, Rh(III) exhibits a pseudo-octahedral geometry, where the Cp* moiety occupies 
three coordination sites, the (O–,N)-donor compound binds in a bidentate manner, and the 
coordination sphere is completed by a chlorido ligand. Complex 1·CH2Cl2 crystallizes in the 
ø
(O ,N) ligands:
6-Mepic 2-QA 3-iQA
H H+ + H+
(a)
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monoclinic space group P21/c, with three molecules per asymmetric unit (Figure 1 shows 
only the molecule A in the asymmetric unit for clarity; for the structures of molecules B and C 
see Figure S4), while complex 2 is a representative of the space group P212121. The Rh to 
ring centroid distance of 2 (1.7655(1) Å) as well as the Rh–Cl distance (2.3991(5) Å) are 
similar to those calculated on average for complex 1·CH2Cl2 (1.767(1) Å and 2.405(8) Å, 
respectively). The measured bond lengths and angles between the metal center and the 
donor atoms were found in the same range as reported for the analogous picolinato complex 
[40]. The metal ion to ring centroid distances (1·CH2Cl2: 1.767(1) Å; 2: 1.7655(1) Å) are 
somewhat shorter than the reported values of the picolinato complex (1.775 Å) while the Rh–
N (2.1278(17) Å) and Rh–O (2.1314(15) Å) bond lengths are comparatively longer in 
complex 1·CH2Cl2. In the picolinato complex, distances of 2.117(3) and 2.108(2) Å were 
obtained for the Rh–N and Rh–O bonds, respectively and are in the same range as bond 
lengths found in complex 2 (Rh–N: 2.1343(16) Å, Rh–O: 2.0991(13)Å) [40]. In complex 
1·CH2Cl2 the ligand 6-Mepic forms a five-membered chelate ring (N1/C1/C6/O1/Rh1) which 
adopts a Rh1-endo envelope conformation with an average deflection angle of ϕ = 20.9(7)° 
measured between the planes defined by N1–C1–C6–O1 and N1–Rh1–O1 atoms (see 
Figure S5). This phenomenon can be explained by the increased steric demand of the 
methyl group which forces a turn out-of-plane of the chelate ring. For complex 2 a 
significantly smaller angle was found (ϕ = 9.77°). Compared to those values, the torsion out-
of-plane found for the comparable chelate ring in the picolinato complex is rather small (ϕ = 
3.37°) [40]. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
 
Figure 1. ORTEP view of complex 1·CH2Cl2 with 50% displacement ellipsoids. Solvent molecules and 
two further independent molecules in the asymmetric unit are omitted for clarity. Selected bond 
distances (Å) and angles (deg): Rh1–N1: 2.1278(17); Rh1–O1: 2.1314(15); Rh1–Cl1: 2.3960(5); 
Rh1–ring centroid: 1.7664(1); N1–Rh1–O1: 76.98(6)°; N1–Rh1–Cl1: 90.39(5)°; O1-Rh1-Cl1: 
90.97(4)°; structures and data for the two other molecules are listed in Figure S4 and Table S2. 
 
Figure 2. ORTEP view of complex 2 with 50% displacement ellipsoids. Selected bond distances (Å) 
and angles (deg): Rh1–N1: 2.1343(16); Rh1–O1: 2.0991(13); Rh1–Cl1: 2.3991(5); Rh1–ring centroid: 
1.7655(1); N1–Rh1–O1: 77.29(6)°; N1–Rh1–Cl1: 85.33(4)°; O1–Rh1–Cl1: 91.55(4)°. 
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Proton dissociation processes of the studied ligands and hydrolysis of the 
[RhCp*(H2O)3]2+ organometallic cation 
Proton dissociation constants of the ligands 6-Mepic, 2-QA and 3-iQA were determined by 
pH-potentiometry and 1H NMR spectroscopy (Table 1), and are in reasonably good 
agreement with data acquired under similar conditions reported in literature [41,42]. The 
proton dissociation constant can be attributed to the deprotonation of the quinolinium (NH+) 
group. The carboxylate remains completely deprotonated in the studied pH range (pH = 
0.7‒11.5). 2-QA has a lower pKa than 3-iQA, a finding that follows the well-known trend for 
the pKa values of the reference compounds: quinoline and isoquinoline [43,44]. 
Hydrolytic behavior of the aquated organometallic cation [RhCp*(H2O)3]2+ has been studied 
previously [27,29], and the structure of the major hydrolysis product, [(RhCp*)2(µ-OH)3]+, was 
characterized by single-crystal X-ray analysis [45]. Overall stability constants for the µ-
hydroxido-bridged dinuclear species ([(RhCp*)2(µ-OH)3]+ and [(RhCp*)2(µ-OH)2]2+) measured 
at various ionic strengths were reported in our previous work [27]. 
Complex formation equilibria of [RhCp*(H2O)3]2+ with 6-Mepic, 2-QA and 3-iQA 
Complex formation with the three different ligands was investigated by the combined use of 
pH-potentiometry, 1H NMR and UV-Vis spectroscopy. The stoichiometry of the formed 
complexes and the equilibrium constants furnishing the best fits to the experimental data are 
listed in Table 1. Stability data for the formerly studied analogous complex with picolinic acid 
are shown here as well for comparison [28]. Notably, the complex formation under these 
conditions was found to be fast and took place within 5-10 minutes for the studied 
complexes. 
Representative pH-potentiometric titration curves of the [RhCp*(H2O)3]2+ – 3-iQA system are 
shown in Figure 3. The titration data revealed almost complete displacement of the 
quinolinium proton by the metal ion due to complex formation already at pH 2; accordingly 
the titration curve containing 1:1 ligand-to-metal ion has the shape of a strong acid–strong 
base titration curvature up to pH ~7. Titration points at pH > 7 initiate various processes 
parallel to the deprotonation of the coordinated water in [RhCp*(L)(H2O)]+ (L= deprotonated 
form of the ligand) resulting in the formation of species of the form [RhCp*(L)(OH)] (see 
Chart S1). Based on the obtained data decomposition of the complex might take place as 
well, giving rise to the hydroxido-bridged compound [(RhCp*)2(µ-OH)3]+, a process that is 
accompanied by ligand release [27]. 
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Figure 3. Representative pH-potentiometric titration curves of the [RhCp*(H2O)3]2+ ‒ 3-iQA system in 
aqueous solution at various metal-to-ligand ratios. Symbols: free ligand (+); 1:2 (○); 1:1.5 (∆) and 1:1 
(□). {cligand = 1.0 mM; T = 25 ˚C; I = 0.20 M (KNO3)}. 
 
UV-Vis spectra recorded at highly acidic conditions (pH ~ 0.7) showed no decomposition of 
the complex 3 (0.1 mM) due to its high stability. Thus, the stability constant for this species 
was determined by ligand competition measurements using spectrophotometry at pH 7.4. 
Ethylenediamine was chosen as competitor since the stability constants for the RhCp* – 
ethylenediamine complex were acquired under the same conditions as applied in this study 
[32]. Upon addition of ethylenediamine to a sample containing [RhCp*(H2O)3]2+ and 3-iQA at 
1:1 metal-to-ligand ratio, clear UV-Vis spectral changes were observed (Figure 4).  
The stepwise displacement of the originally metal-bound 3-iQA by ethylenediamine results in 
the formation of complex [RhCp*(en)(H2O)]+, thus unbound 3-iQA and excess amounts of 
ethylenediamine (making no contribution to the measured absorbance) are present in the 
sample. The stability constant of 3 could be calculated by deconvolution of the recorded 
spectra using the computer program PSEQUAD [46]. Including this value as a fixed 
constant, the pKa of the mono complex could be calculated from the pH-potentiometric 
titration data (Table 1). 
 
  
2
4
6
8
10
-2 -1 0 1 2 3 4
pH
base equivalent / ((n(KOH)–n(HNO3)extra)/nlig)
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Table 1. Proton dissociation constants (pKa) of the studied ligands and overall stability constants (logβ), pKa, and 
pM7.4 values of their [RhCp*(L)(H2O)]+ complexes in chloride-free aqueous solutions determined by various 
methods, H2O/Cl‒ exchange constants (logK’) for the same complexes, and the 1H NMR chemical shifts of 
CH3(Cp*) protons of the indicated complexes {T = 25 °C; I = 0.2 M (KNO3)}.[a] 
 
method L: pic[b] 
6-Mepic 
1 
2-QA 
2 
3-iQA 
3 
pKa (HL) 
 
pH-metry 
1H NMR 
5.21 
– 
5.89(1) 
5.91(1) 
4.83(1) 
4.79(1) 
5.62(2) 
5.57(2) 
logβ [RhCp*(L)(H2O)]+  pH-metry 9.18 9.79(7) 9.49(4) 10.60(3)[c] 
pKa [RhCp*(L)(H2O)]+ pH-metry 9.32 9.49(10) 9.31(5) 9.26(1) 
 
1H NMR 9.38 9.54(1) 9.42(1) 9.49(1) 
pM7.4[d]  5.35 5.76 5.57 6.29 
logK’ (H2O/Cl–)[e] UV-Vis 2.20 2.10(1) 2.33(1) 2.05(1) 
δ CH3(Cp*) (ppm) [RhCp*(L)(H2O)]+ 
[RhCp*(L)(OH)] 
1.70 
1.65 
1.63 
1.57 
1.62 
1.56 
1.74 
1.68 
[a] Standard deviations (SD) are in parenthesis. Hydrolysis products of the organometallic cation:  
logβ [(RhCp*)2(µ-OH)2]2+ = ‒8.53, logβ [(RhCp*)2(µ-OH)3]+ = ‒14.26 at I = 0.20 M (KNO3) taken from Ref. [27]. [b] 
Taken from Ref. [28]. [c] Determined by UV-Vis spectrophotometry via competition studies measured at pH 7.40, 
the competitor ligand was ethylenediamine see details in experimental section. [d] pM7.4 = –log[M], where [M] is 
the equilibrium concentration of the ligand-free, unbound metal ion in its different forms: [RhCp*(H2O)3]2+, 
[(RhCp*)2(µ-OH)i](4-i)+ (i = 2 or 3) {cM = 1 mM; M:L = 1:1, pH = 7.4}. [e] For the [RhCp*(L)(H2O)]+ + Cl− ⇌ 
[RhCp*(L)Cl] + H2O equilibrium determined at various total chloride ion concentrations by UV-Vis. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
 
Figure 4. UV–Vis spectra of the [RhCp*(H2O)3]2+ – 3-iQA – ethylenediamine system recorded at pH 
7.40 at various ethylenediamine-to-3-iQA ratios (dashed spectrum is calculated as the sum of the 
spectra of [RhCp*(ethylenediamine)(H2O)]2+ and 3-iQA). Inset shows the measured (♦) and fitted 
(solid line) absorbance values at 334 nm plotted against the ethylenediamine (en)-to-3-iQA ratios. 
Spectra are background subtracted spectra.  {cRhCp* = c3-iQA = 99 µM; cethylenediamine = 0‒148 µM; pH 
= 7.40 (20 mM phosphate buffer); T = 25 ˚C; incubation time = 24 h; I = 0.20 M (KNO3) ℓ = 0.5 cm)  
In order to investigate equilibrium processes, 1H NMR titrations were carried out. The NMR 
spectra in Figure 5 show one set of peaks at pH values varying between 1.97 and 8.13 
which confirm the predominant formation of complex 3 as neither unbound 3-iQA nor Rh(III)-
Cp* fragment can be detected in this pH range. At pH > 7.75, an equilibrium between the 
aquated complex and the mixed hydroxido species [RhCp*(L)(OH)] is reached, with very 
high exchange rates that cannot be resolved in the NMR time scale. These exchange 
processes cause a high field shift of proton resonances, thereby providing a means of 
calculation of the pKa value of the complex (Table 1).  
 
pH
11.51
10.75
10.08
9.68
9.26
8.88
8.59
8.13
7.75
6.39
1.97
9.5       9.0     8.5        8.0       // 1.8        1.6
δ / (ppm)
■
●
●
●
♥ ♦
♥
▲
♦
▲■
o▼
o
▼
■♥ ♦ ▲o ▼
♥ ●
●
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Figure 5. 1H NMR spectra of the [RhCp*(H2O)3]2+ – 3-iQA (1:1) system in aqueous solution recorded 
at the indicated pH values; peak assignation is indicated in the figure for the complex bound (black 
symbols) and unbound (grey symbols) species {cRhCp* = c3-iQA = 1 mM; T = 25 ˚C; I = 0.20 M (KNO3); 
10% D2O}. 
Furthermore, peaks of the hydroxido-bridged dimer [(RhCp*)2(µ-OH)3]+ as well as peaks 
representing the deprotonated free ligand 3-iQA appear at pH > 9.26 (Figure 5). However, 
fairly low peak integrals indicate the rather small extent to which the complexes decompose. 
Concentration distribution curves were computed including the stability constants determined 
by competition measurements and pH-potentiometric titrations. Acquired data are in good 
agreement with the molar fractions calculated on the basis of NMR peak integrals along with 
the chemical shift values of the Cp*
 
methyl protons (Figure 6).  
 
Figure 6. Concentration distribution curves (solid lines) for the [RhCp*(H2O)3]2+ – 3-iQA (1:1) system 
in aqueous solution calculated on the basis of the stability constants determined and the 1H NMR 
peak integrals for the Cp* methyl protons of [(RhCp*)2(µ-OH)3]+ (∆), and pH-dependent chemical shift 
values (●) of the Cp* methyl protons. {cRhCp* = c3-iQA = 1 mM; T = 25 ˚C; I = 0.20 M (KNO3); 10% D2O}.  
A similar solution speciation model was applied in the case of complexes 1 and 2. Stability 
constants could be computed from the pH-potentiometric data directly and were found to be 
somewhat lower than those obtained for 3 (Table 1). It can be concluded that the 
deprotonation constants (pKa) of 1–3 are fairly high in all cases, and the aqua complex is the 
predominant form (~99%) at physiological pH. Instead of the direct comparison of stability 
constants, pM values were calculated at various pH values (see Table 1 and Figure S6). 
The pM value, which is defined as the negative logarithm of the equilibrium concentrations of 
the unbound metal ion under the given conditions (pH, analytical concentrations of the ligand 
and metal ion), was introduced by Raymond et al. [47] to gauge the relative affinities of 
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ligands towards a metal ion. A higher pM value indicates a stronger metal ion binding ability. 
In our case both the organometallic cation [RhCp*(H2O)3]2+ as well as the µ-hydroxido 
dinuclear complexes ([(RhCp*)2(µ-OH)i](4-i)+ (i = 2 or 3)) have to be considered as unbound 
species. In this way we take into account equilibria occurring simultaneously with the metal-
ligand complex formation such as (de)protonation processes of the ligand, and hydrolysis of 
the organometallic fragment. The calculations reveal the following stability trend at 
physiological pH: pic < 2-QA < 6-Mepic << 3-iQA (Table 1). Thus, the extension of the 
picolinic acid structure by 6-methylation or benzene conjugation increases the complex 
stability of the respective RhCp* derivatives. The three investigated ligands form RhCp* 
complexes of pronounced stability. Based on their stability constants, decomposition does 
not occur even at low micromolar concentrations to a measurable extent. This assumption 
was confirmed both in chloride free and 0.2 M KCl containing aqueous solution, using the 
RhCp* – 3-iQA system in a 1:1 ratio: a dilution series (from 2 mM down to 4 µM) was 
prepared at pH 7.40 and the recorded UV-Vis spectra, after normalization, were identical 
under the applied conditions, which indicates that there is no complex decomposition in the 
studied concentration range (see Figure S7).  
With the help of pM values, we can directly compare the RhCp* binding abilities of the 
studied ligands and previously studied (O–,O) donating ligand deferiprone and the (N,N) 
donating 2,2´-bipyridine (Figure S6), thus the solution stabilities of the complexes become 
comparable under the given conditions. The pM7.4 value of 2 is more than half an order of 
magnitude higher compared to that of the RhCp* deferiprone complex with an (O–,O) 
coordination mode (4.99 [28]), but more than two orders of magnitude lower than the pM7.4 
value of the 2,2´-bipyridine complex (7.82 [32]). 
 
Chloride ion affinity and lipophilicity of the [RhCp*(L)(H2O)]+ complexes 
Beside metal complex stability, many other factors impact the pharmacological behavior. 
Complete or partial displacement of the chloride ion by an aqua ligand (Chart S1) is 
considered a crucial step in the activation process of half-sandwich complexes. The aquation 
of the well-known anticancer drug cisplatin has been thoroughly studied and the aquated 
form of the complex was identified as the active species. This hydrolysis is controlled both 
kinetically and thermodynamically; the thermodynamic driving force is thought to be the 
gradient in chloride ion concentration (chloride ion content in blood serum: 100 mM > cell 
plasma: ~24 mM > cell nucleus: ~4 mM) [48]. A dependence of cytotoxic efficacy on chloride 
ion affinity has been observed for several [Ru(II)(η6-arene)] complexes [49-51]. In the case 
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of the studied RhCp* complexes of the form [Rh(Cp*)(L)(H2O)]+ (similarly to previously 
characterized complexes [27,28,32]) the chloride-water exchange process was found to be 
fast and takes place within a few minutes. Figure S8 shows the spectral changes of 1 upon 
the increase in chloride ion concentration. The logK’ (H2O/Cl−) constants (Table 1) were 
calculated by the deconvolution of UV–Vis spectra and were found to be significantly high 
(>2), thus they represent a strong affinity of these complexes towards the chloride ions. With 
the aid of aqua/chlorido exchange constants, we can estimate the ratio of the aqua and the 
chlorido complexes at chosen chloride ion concentrations. At a chloride concentration of 
100 mM, 92% of 3 and 96% of 2 appear in the neutral chlorido form, while at chloride ion 
concentrations comparable to those of the cell nucleus (4 mM), 69% and 54% of these 
complexes are present as the more reactive aqua species.  
One other notable consequence of the aqua/chlorido exchange equilibrium is the altered net 
charge of the complexes (see Chart S1). Since the lipo/hydrophilic character of a compound 
is strongly influenced by its charge, distribution coefficients at pH 7.4 (D7.4) were determined 
for 1–3 (and additionally for the picolinate complex for comparison) at various chloride ion 
concentrations.  
 
Figure 7. Logarithm of distribution coefficients (log D7.4) of the RhCp* precursor, [RhCp*(pic)(H2O)]+ 
and complexes 1–3 at pH 7.40 measured at various KCl concentrations (as indicated in the figure) 
{ccompound = 200 µM; T = 25 °C, in 20 mM phosphate buffer}. Log D7.4 values of the ligands measured at 
0.1 M KCl content for comparison: 2-QA: –1.3(1), 3-iQA: –1.41(4) and pic: <–2.0 [52], 6-Mepic: <–2.0 
[52].  
Figure 7 (and Table S3) illustrates the log D7.4 values of the complexes and the RhCp* 
precursor at varying KCl concentrations and those of the respective ligands. The ligands pic 
and 6-Mepic definitely possess hydrophilic character owing to the deprotonated carboxylate 
group, while 2-QA and 3-iQA are somewhat less hydrophilic due to the more extended 
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aromatic structure. The organorhodium fragment RhCp* itself displays a chloride ion 
dependent lipo/hydrophilic character: less than 1% of RhCp* is detected in the n-octanol 
phase in chloride ion free solution (log D7.4 < –2), while in the presence of 0.1 M KCl already 
a significant amount (20%) is found in the organic phase (log D7.4 = –0.61(6)). The ratio 
slightly increases at a concentration of 0.50 M KCl (26%, log D7.4 = -0.46(3)). Considering the 
hydrolysis tendency of the organometallic cation [RhCp*(H2O)3]2+ at pH 7.4 not primarily the 
water-chlorido but the hydroxido-chlorido exchange and consequently a dimer-monomer 
redistribution is the predominant process. In our studies the lipophilic character of 1–3 was 
found to increase in the following order (independent of absence or presence of chloride 
ions): pic complex < 1 << 2 < 3, analogous to the lipophilicity of the free ligands. Moreover, 
log D7.4 values obtained for the complexes in the presence of 0.10 M KCl, are distinctly 
higher (0.6–0.7 orders of magnitude) than values acquired in samples without chloride ions. 
It is noteworthy that the lipo/hydrophilic character of the complexes is not only affected by 
the type of the ligands but also by their affinity for chloride ions and the chloride ion 
concentration in solution. This feature may facilitate cell accumulation of the complexes via 
passive transport since the chlorinated complex can pass easier across the cell membrane 
compared to its charged, aquated form.  
Cytotoxic activity in cancer cell lines 
In our previous work, RhCp* complexes bearing the hydroxypyrone ligands maltol and 
allomaltol, the hydroxypyridinone derivative deferiprone, picolinic acid and 8-
hydroxyquinoline, were investigated with regard to their anticancer potential in various 
human cancer cell lines [27,28,33]. These complexes were found to exhibit minor cytotoxicity 
with the exception of the deferiprone and 8-hydroxyquinoline-based complexes. In general, 
no correlation was observed between the IC50 values and the calculated pM values, implying 
an independence of cytotoxicity from solution stability. The pKa values of the complexes are 
rather high, hence the lack of cytotoxicity cannot be associated with the formation of the less 
active mixed hydroxido species at pH 7.4 [50]. At the same time the analogous Ru(II)(η6-p-
cymene) picolinato complex resulted in IC50 values of 36–82 µM measured in human cancer 
cell lines, such as cervix carcinoma (HeLa) and melanoma cells (FemX) [53]. Cytotoxicity 
data for the related Ru(II)(η6-p-cymene) complexes of 6-Mepic and 3-iQA have been 
acquired and published previously. The 3-iQA-based Ru(II) complex shows moderate activity 
in HeLa (45.35 µM), FemX (18.48 µM) and A549 (25.76 µM) cells. Furthermore, a high IC50 
value in normal cells (MRC-5, 84.18 µM) supports its tumor selective cytotoxic activity [38]. 
On the other hand the Ru(II)(η6-p-cymene) complex of 6-Mepic showed low activity in the 
same cell lines (HeLa: 278 µM, FemX: 169 µM, A549: > 300 µM) [38]. The cytotoxic activity of 
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RhCp* complexes 1–3 and the corresponding free ligands have been evaluated by means of 
the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide) in the human cancer cell lines A549 (non-small cell lung cancer), SW480 (colon 
carcinoma) and CH1/PA-1 (ovarian teratocarcinoma). In general no considerable activity of 
the complexes was found with the exception of complex 3 in CH1/PA-1 cells (Table 2). 
Cytotoxic potency of the free ligands is poor to virtually non-existent, with only 3-iQA yielding 
IC50 values in the tested range of up to 400 µM. One possible reason for poor anticancer 
activities of compounds 1–3 could be an impeded aquation due to the exceptionally high 
affinity of the complexes for chloride ions. This correlation has already been pointed out for 
related Ru(II), Os(II) and Ir(III) complexes [34-36]. However, high chloride ion affinity may 
hinder not only the aquation of the complexes but also possible monodentate coordination of 
bio-ligands (such as proteins or DNA nucleobases). Additionally, other physico-chemical 
properties such as lipophilicity or redox activity etc. can influence the cytotoxic activity. 
Consequently, the increased lipophilicity and higher stability in solution found for complex 3 
(vide supra) as well as a certain cytotoxic potency inherent in the 3-iQA ligand per se might 
contribute to its higher cytotoxicity in CH1/PA-1 cells.  
Table 2. In vitro cytotoxicity (IC50 values in µM in three human cancer cell lines) of the RhCp* complexes of 6-
Mepic (1), 2-QA (2) and 3-iQA (3) and pic as well as the corresponding free ligands for comparison.[a] 
IC50 [µM] A549 SW480 CH1/PA-1 
RhCp* Complexes 
1 (6-Mepic) 356 ± 36 319 ± 38 221 ± 19 
2 (2-QA) >200 >100 115 ± 36 
3 (3-iQA) 174 ± 5 161 ± 7 10.2 ± 0.4 
pic[b] 343 ± 24 283 ± 65 258 ± 6 
Ligands    
6-Mepic >400 >400 >400 
2-QA >400 >400 >400 
3-iQA 288 ± 14 360 ± 35 85 ± 11 
[a] 96 h exposure. [b] Data taken from Ref. [28]. 
Conclusions 
The evaluation of stability and speciation of organometallic compounds is of high value for 
the assessment of their behavior under physiological conditions. Data presented within this 
work were acquired by the application of a variety of methods, comprising 1H NMR and  
UV-Vis spectroscopy, pH potentiometry, X-ray diffraction analysis and cytotoxicity tests. By 
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means of these methods we could demonstrate exclusive formation of the mono-ligand 
complexes, such as [RhCp*(L)(H2O)]+ (L = deprotonated 6-Mepic, 2-QA or 3-iQA) and 
[RhCp*(L)(OH)], depending on the pH. Formation of the hydroxido complexes could be 
characterized by determination of relatively high pKa values (> 9.25), while complexes of the 
form [RhCp*(L)(H2O)]+ predominate at physiological pH even in the micromolar 
concentration range. The ligand 3-iQA forms complexes of the highest stability with RhCp* in 
this series. In general, the stability of the complexes formed with all three ligands 
significantly exceeds that of hydroxypyr(idin)ones, such as maltol or deferiprone, although it 
stays below the stability of complexes with (N,N) donor ligands such as ethylenediamine or 
2,2’-bipyridine. 
Chloride ions acting as competitive ligands are able to suppress the aquation to some 
extent. This process may play an important role in the mechanism of action of this type of 
organometallic complexes. The extent of the chloride/water exchange was shown to depend 
on the chloride concentrations in the medium as well as on the thermodynamic exchange 
constant. H2O/Cl− co-ligand exchange constants for the complexes 1–3 were determined, 
and all compounds are able to retain the chlorido ligand at the third coordination site to an 
extent comparable to that of RhCp* complexes with picolinic acid, ethylenediamine or 2,2’-
bipyridine. Based on these constants it can be predicted that more than 90% of the 
respective complexes exist as the chlorido complex at the chloride concentration 
corresponding to those in human blood serum. As a consequence of the replacement of the 
aqua ligand by a chlorido ligand, the net charge of the complexes changes from +1 to 
neutral, thus the co-ligand exchange strongly influences their lipophilicity. It can therefore be 
assumed that the higher chloride ion content results in a more lipophilic character. The fact 
that minor cytotoxic effects were observed in in vitro tests performed with complexes 1–3 
could be explained by the high affinity of complexes for chloride ions which might suppress 
the activation of the investigated compounds. 
Overall, the extension of the picolinic acid structure by 6-methylation or annellation of a 
benzene ring results in increased stability and lipophilicity of the synthesized RhCp* 
complexes, but the influence on the anticancer properties is only minor. 
Experimental Section 
Materials 
All solvents were of analytical grade and used without further purification. 6-Mepic, 2-QA, 3-
iQA, KCl, KNO3, AgNO3, HCl, HNO3, KOH, 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 
NaH2PO4, Na2HPO4 and ethylenediamine were purchased from Sigma-Aldrich in puriss 
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quality. RhCl3 was purchased from Johnson Matthey. Doubly distilled Milli-Q water was used 
for sample preparation. The dimeric rhodium precursor [rhodium(III)(η5-1,2,3,4,5-
pentamethylcyclopenta-dienyl)(µ-Cl)Cl]2 ([RhCp*(µ-Cl)Cl]2) was prepared according to 
literature procedures [39]. The exact concentration of the ligand stock solutions together with 
the proton dissociation constants were determined by pH-potentiometric titrations with the 
use of the computer program HYPERQUAD [54]. The aqueous [RhCp*(H2O)3](NO3)2 stock 
solution was obtained by dissolving an exact amount of [RhCp*(µ-Cl)Cl]2 in water followed by 
the removal of chloride ions by addition of equivalent amounts of AgNO3. The exact 
concentration of [RhCp*(H2O)3]2+ was determined by pH-potentiometric titrations employing 
stability constants for [(RhCp*)2(µ-OH)i](4-i)+ (i = 2 or 3) complexes [27]. 
 
Synthesis of RhCp* complexes with 6-Mepic, 2-QA and 3-iQA 
General procedure for the synthesis of complexes 1-3 
The ligand (1 eq) and sodium methoxide (1.1 eq) were dissolved in dry methanol (10 mL) 
and after stirring at room temperature for 15 min, [RhCp*(µ-Cl)Cl]2 (0.9 eq) was added. The 
mixture was stirred under argon atmosphere and at room temperature for 24 h. The solvent 
was subsequently removed under reduced pressure; the obtained residue was taken up in 
CH2Cl2 and filtered to remove insoluble reaction by-products. The filtrate was concentrated 
to a volume of 2 mL under reduced pressure. Precipitation with n-hexane afforded the 
desired product in moderate to good yields (53–64%). 
1H NMR spectra were recorded at 25 °C and 500.10 MHz and 13C{H} NMR spectra at 25 °C 
and 125.75 MHz using a Bruker FT-NMR spectrometer Avance III™ 500 MHz. For the 
characterization with NMR spectroscopy CDCl3 was used as solvent. Elemental analyses 
were carried out on a Perkin Elmer 2400 CHN Elemental Analyser at the Microanalytical 
Laboratory (University of Vienna). If not stated otherwise, the substances were synthesized 
and purified according to general procedures. 
Chlorido[(6-methylpyridine-κN-2-carboxylato-κO)(η5-1,2,3,4,5-
pentamethylcyclopentadienyl)rhodium(III)] (1): The reaction was performed according to 
the general procedure using 6-Mepic (74 mg, 0.54 mmol), sodium methoxide (32 mg, 0.594 
mmol) and [RhCp*(µ-Cl)Cl]2 (150 mg, 0.243 mmol). The product was obtained as orange 
crystals. Yield: 127 mg (64%); 1H NMR (500.10 MHz, CDCl3) δ 7.98 (d, 3J (H,H) = 8 Hz, 1H, 
CH3); 7.80 (dd, 3J (H,H) = 8 Hz, 3J (H,H) = 8 Hz,1H, CH4); 7.47 (d, 3J (H,H) = 8 Hz, 1H, 
CH5); 2.92 (s, 3H, CH3); 1.67 (s, 15H, CH3,Cp*) ppm. 13C NMR (125.75 MHz, CDCl3) δ 170.6 
(C7); 159.4 (C6); 153.4 (C2); 139.0 (CH4); 128.3 (CH5); 124.6 (CH3); 94.1 (d, 1J(Rh,C) = 
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9 Hz, CCp*); 26.5 (CH3,6-Mepic); 9.3 (CH3,Cp*) ppm. Elemental analysis for C17H21ClNO2Rh·0.5 
H2O calc. C 48.76, H 5.30, N 3.35; found C 48.41, H 5.31, N 3.40.  
Chlorido[(2-quinoline-κN-carboxylato-κO)(η5-1,2,3,4,5-
pentamethylcyclopentadienyl)rhodium(III)] (2): The reaction was performed according to 
the general procedure using 2-QA (94 mg, 0.54 mmol, 1 eq), sodium methoxide (32 mg, 
0.594 mmol, 1.1 eq) and [RhCp*(µ-Cl)Cl]2 (150 mg, 0.243 mmol, 0.45 eq). The product was 
obtained as orange crystals. Yield: 132 mg (61%); 1H NMR (500.10 MHz, CDCl3) δ 8.46 (d, 
3J (H,H) = 9 Hz, 1H, CH8); 8.38 (d, 3J (H,H) = 9 Hz, 1H, CH4); 8.22 (d, 3J (H,H) = 9 Hz, 1H, 
CH3); 7.95 (d, 3J (H,H) = 9 Hz, 1H, CH5); 7.90 – 7.86 (m, 1H, CH6); 7.74 – 7.70 (m, 1H, 
CH7); 1.65 (CH3,Cp*) ppm. 13C NMR (125.75 MHz, CDCl3) δ 170.5 (C9); 154.5 (C2); 145.2 
(C8a); 139.9 (CH4); 131.2 (CH7); 131.1 (C4a); 129.4 (CH8); 129.1 (CH6); 128.9 (CH5); 
123.3 (CH3); 94.3 (d, 1J(Rh,C) = 9 Hz, CCp*); 9.3 (CH3,Cp*) ppm. Elemental analysis for 
C20H21ClNO2Rh calc. C 53.89, H 4.75, N 3.14; found C 53.61, H 4.66, N 3.26 
Chlorido[(3-isoquinoline-κN-carboxylato-κO)(η5-1,2,3,4,5-
pentamethylcyclopentadienyl)rhodium(III)] (3): The reaction was performed according to 
the general procedure using 3-iQA acid (94 mg, 0.54 mmol, 1 eq), sodium methoxide (32 
mg, 0.594 mmol, 1.1 eq) and [RhCp*(µ-Cl)Cl]2 (150 mg, 0.243 mmol, 0.90 eq). The product 
was obtained as orange crystals. Yield: 115 mg (53%); 1H NMR (500.10 MHz, CDCl3) δ 9.23 
(s, 1H, CH1); 8.48 (s, 1H, CH4); 8.08 (d, 3J (H,H) = 8 Hz, 1H, CH8); 7.96 (d, 3J (H,H) = 8 Hz, 
1H, CH5); 7.86 – 7.81 (m, 1H, CH6); 7.78 – 7.74 (m, 1H, CH7); 1.76 (s, 15H, CH3Cp*) ppm. 
13C NMR (125.75 MHz, CDCl3) δ 170.92 (C9); 152.9 (CH1); 145.3 (C3); 136.5 (C8a); 132.9 
(CH6); 130.6 (C4a); 129.9 (CH7); 128.4 (CH5); 127.8 (CH8); 125.5 (CH4); 93.9 (d, 1J(Rh,C) 
= 9 Hz, CCp*); 9.2 (CH3,Cp*) ppm. Elemental analysis for C20H21ClNO2Rh·0.5H2O calc. C 
52.82, H 4.88, N 3.08; found C 52.99, H 4.67, N 3.11 
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Crystallographic structure determination: Single crystals of complexes [RhCp*(L)Cl] 
formed with 6-Mepic (1·CH2Cl2) and 2-QA (2) were analyzed on a Bruker D8 Venture 
diffractometer equipped with multilayer monochromator, Mo K/a INCOATEC micro focus 
sealed tube and Kryoflex II cooling device at 100 K. The single crystals were positioned at 
35 mm from the detector and 2461 or 2076 frames for 2.4 or 8 s exposure time over 0.4° 
scan width were measured for complexes 1 and 2, respectively. The structures were solved 
by direct methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms 
were refined with anisotropic displacement parameters. Hydrogen atoms were inserted at 
calculated positions and refined with a riding model. The following computer programs were 
used: frame integration, Bruker SAINT software package [55] using a narrow-frame 
algorithm; absorption correction, SADABS [56]; structure solution, SHELXS-2013 [57]; 
refinement, SHELXL-2013 [57], OLEX2 [58], SHELXLE [59]; molecular diagrams, OLEX2 
[58]. The crystallographic data files for the complexes have been deposited with the 
Cambridge Crystallographic Database as CCDC 1508154 (1·CH2Cl2) and CCDC 1508153 
(2). Crystal data and structure refinement details for complexes 1·CH2Cl2 and 2 are given in 
Table S1.  
 
pH-Potentiometric measurements: pH-potentiometric measurements determining proton 
dissociation constants of ligands and overall stability constants for tested RhCp* complexes 
were carried out in at 25.0 ± 0.1 °C in water and at a constant ionic strength of 0.20 M KNO3. 
The titrations were performed in a carbonate-free KOH solution (0.20 M). The exact 
concentrations of HNO3 and KOH solutions were determined by pH-potentiometric titrations. 
An Orion 710A pH-meter equipped with a Metrohm “double junction” combined electrode 
(type 6.0255.100) and a Metrohm 665 Dosimat burette were used for the pH-potentiometric 
measurements. The electrode system was calibrated to the pH = −log[H+] scale by means of 
blank titrations (strong acid vs. strong base: HNO3 vs. KOH), as suggested by Irving et al. 
[60]. The average water ionization constant, pKw, was determined as 13.76 ± 0.01 at 25.0 
°C, I = 0.20 M (KNO3), which is in accordance to literature [61]. The pH-potentiometric 
titrations were performed in the pH range between 2.0 and 11.5. The initial volume of the 
samples was 10.0 mL. The ligand concentration was 1.0 mM and was investigated at metal 
ion-to-ligand ratios of 1:1, 1:1.5, and 1:2. The accepted fitting between the measured and 
calculated titration data points regarding the volume of the titrant was < 10 µL. Samples 
were degassed by bubbling purified argon through them for about 10 minutes prior to the 
measurements and the inert gas was also passed over the solutions during the titrations. 
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Calculations were performed with the computer program PSEQUAD [46] in the same way as 
in our previous works [27,28,32,33]. 
UV–Vis spectrophotometric, 1H NMR titrations and determination of distribution 
coefficients: A Hewlett Packard 8452A diode array spectrophotometer was used to record 
the UV-Vis spectra in the interval 200–800 nm. The path length (ℓ) was 0.1, 0.2, 0.5, 1, 2, or 
4 cm. The overall stability constant of complex 3 (with 3-iQA) was determined 
spectrophotometrically by competition titrations using the complex in the presence of 
ethylenediamine at pH 7.40 (20 mM phosphate buffer) and at an ionic strength of 0.20 M 
(KNO3). Samples contained 99 µM [RhCp*(H2O)3]2+ and 99 µM 3-iQA, while the 
concentration of ethylenediamine was varied between 0–148 µM. Absorbance data were 
recorded in a wavelength interval between 270 and 450 nm after 24 h of incubation. UV-Vis 
spectra were used to investigate the H2O/Cl− exchange processes of complexes at 250 µM 
(1, 2) or 100 µM (3) concentration, at pH 7.40 (20 mM phosphate buffer) as a function of 
chloride concentrations (0–330 mM).  
D7.4 values of the [RhCp*(L)(Z)] complexes 1–3 (where Z = H2O/Cl–) and the ligands as well 
as the organorhodium RhCp* fragment were determined by the traditional shake-flask 
method in n-octanol/buffered aqueous solution at pH 7.40 at various chloride concentrations 
using UV-Vis photometry as described in our former work [33,52]. 
1H NMR studies were carried out on a Bruker Ultrashield 500 Plus instrument. All 1H NMR 
spectra were recorded with the WATERGATE water suppression pulse scheme using DSS 
internal standard. Ligands 6-Mepic, 2-QA and 3-iQA were dissolved in a 10% (v/v) D2O/H2O 
mixture to yield a concentration of 1 or 2 mM and were titrated at 25 °C, at I = 0.20 M (KNO3) 
in absence or presence of [RhCp*(H2O)3]2+ at 1:1 metal-to-ligand ratio. Stability constants for 
the complexes were calculated by the computer program PSEQUAD [46]. 
Cell lines, culture conditions and cytotoxicity tests in cancer cell lines 
Cell lines and culture conditions: CH1/PA-1 cells (identified via STR profiling as PA-1 
ovarian teratocarcinoma cells by Multiplexion, Heidelberg, Germany) were a gift from Lloyd 
R. Kelland, CRC Center for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK. 
SW480 (human adenocarcinoma of the colon), and A549 (human non-small cell lung 
cancer) cells were provided by Brigitte Marian (Institute of Cancer Research, Department of 
Medicine I, Medical University of Vienna, Austria). All cell culture reagents were obtained 
from Sigma-Aldrich and plasticware from Starlab (Germany). Cells were grown in 75 cm² 
culture flasks as adherent monolayer cultures in minimum essential medium (MEM) 
supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 4 mM L-
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glutamine, and 1% non-essential amino acids (from 100 × ready-to-use stock). Cultures 
were maintained at 37 °C in humidified atmosphere composed of 95% air and 5% CO2. 
MTT assay: Cytotoxic effects were determined by means of a colorimetric microculture 
assay (MTT assay). For this purpose, cells were harvested from culture flasks by 
trypsinization and seeded in 100 µL/well aliquots into 96-well microculture plates. Cell 
densities of 1.0×103 cells/well (CH1/PA-1), 2.0×103 cells/well (SW480), and 3.0×103 
cells/well (A549) were chosen in order to ensure exponential growth of untreated controls 
throughout the experiment. Cells were allowed to settle and resume exponential growth in 
drug-free complete culture medium for 24 h. Test compounds (1 and 2) were then dissolved 
in DMSO first, diluted in complete culture medium and added to the plates where the final 
DMSO content did not exceed 0.5%, whereas 3 was dissolved in pure complete culture 
medium. After 96 h of exposure, all media were replaced with 100 µL/well of a 1:7 
MTT/RPMI 1640 solution (six parts of RPMI1640 medium supplemented with 10% heat-
inactivated fetal bovine serum and 4 mM L-glutamine; one part of 5 mg/mL MTT reagent in 
phosphate-buffered saline (PBS)). After incubation for 4 h, the supernatants were removed 
and the formazan crystals formed by viable cells were dissolved in 150 µL DMSO per well. 
Optical densities at 550 nm were measured with a microplate reader (BioTek ELx808) using 
a reference wavelength of 690 nm to correct for unspecific absorption. The quantity of viable 
cells was expressed as percentage of untreated controls, and 50% inhibitory concentrations 
(IC50) were calculated from concentration-effect curves by interpolation. Evaluation is based 
on means from three independent experiments, each comprising three replicates per 
concentration level. 
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